1132709-15-9

Basic information

• Product Name: ((R)-3-Methyl-1-((R)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid
• Synonyms: ((R)-3-Methyl-1-((R)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid;(1R,2R)-BortezoMib;N-(2-Pyrazinecarbonyl)-D-phenylalanine-L-leucine boronic anhydride;[(1R)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid;(1R,2R)-Bortezomib Impurity;[(1R)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid;B-[(1R)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid;Bortezomib USP Related Compoud H
• CAS NO: 1132709-15-9
• Molecular Formula: C₁₉H₂₅BN₄O₄
• Molecular Weight: 384.2372
• Product Categories: Chiral Reagents, Boron Derivatives, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1132709-15-9.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.214±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 9.66±0.43(Predicted)
• CAS DataBase Reference: ((R)-3-Methyl-1-((R)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: ((R)-3-Methyl-1-((R)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid(1132709-15-9)
• EPA Substance Registry System: ((R)-3-Methyl-1-((R)-3-phenyl-2-(pyrazine-2-carboxaMido)propanaMido)butyl)boronic acid(1132709-15-9)

Safety Data

• Hazardous Substances Data: 1132709-15-9(Hazardous Substances Data)

Usage

Uses

(1R,2R)-Bortezomib is a diastereomer of Bortezomib (B675700), the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway

Upstream product

• 18942-49-9 Boc-D-Phe-OH 

Relevant articles and documents

Structure-Based Design of Selective LONP1 Inhibitors for Probing in Vitro Biology

LONP1 is an AAA+ protease that maintains mitochondrial homeostasis by removing damaged or misfolded proteins. Elevated activity and expression of LONP1 promotes cancer cell proliferation and resistance to apoptosis-inducing reagents. Despite the importance of LONP1 in human biology and disease, very few LONP1 inhibitors have been described in the literature. Herein, we report the development of selective boronic acid-based LONP1 inhibitors using structure-based drug design as well as the first structures of human LONP1 bound to various inhibitors. Our efforts led to several nanomolar LONP1 inhibitors with little to no activity against the 20S proteasome that serve as tool compounds to investigate LONP1 biology.